Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Birgitte Smith‐Sørensen(Norwegian Cancer Society), A‐L Børresen‐Dale(Norwegian Cancer Society), J. Kærn(University of Oslo), Claes G. Tropé, Ruth Holm(University of Aleppo), Anne Dørum(Oslo University Hospital)
Cited by 56
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.
|PubMed|1993|589
Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers
|PLoS ONE|2011|222
Prognostic significance of TP53 alterations in breast carcinoma
|British Journal of Cancer|1993|168